Rational Targets of Therapy in Extranodal NK/T-Cell Lymphoma.
Ajay MajorPierluigi PorcuBradley M HaverkosPublished in: Cancers (2023)
Extranodal NK/T-cell lymphoma (ENKTL) is an aggressive extranodal non-Hodgkin lymphoma (NHL) with poor outcomes, particularly in advanced-stage and relapsed/refractory disease. Emerging research on molecular drivers of ENKTL lymphomagenesis by next-generation and whole genome sequencing has revealed diverse genomic mutations in multiple signaling pathways, with the identification of multiple putative targets for novel therapeutic agents. In this review, we summarize the biological underpinnings of newly-understood therapeutic targets in ENKTL with a focus on translational implications, including epigenetic and histone regulatory aberrations, activation of cell proliferation signaling pathways, suppression of apoptosis and tumor suppressor genes, changes in the tumor microenvironment, and EBV-mediated oncogenesis. In addition, we highlight prognostic and predictive biomarkers which may enable a personalized medicine approach toward ENKTL therapy.
Keyphrases
- signaling pathway
- cell proliferation
- dna methylation
- pi k akt
- diffuse large b cell lymphoma
- oxidative stress
- copy number
- cell cycle arrest
- acute myeloid leukemia
- gene expression
- epstein barr virus
- genome wide
- acute lymphoblastic leukemia
- bioinformatics analysis
- transcription factor
- epithelial mesenchymal transition
- cell cycle
- multiple myeloma
- stem cells
- hodgkin lymphoma
- cell death
- metabolic syndrome
- skeletal muscle
- single molecule